Antisense antiviral compounds and methods for treating a filovirus infection

• US 7,524,829 B2
• Filed: 10/31/2005
• Issued: 04/28/2009
• Est. Priority Date: 11/01/2004
• Status: Active Grant

• Current Assignee: Sarepta Therapeutics, Inc., United States Army Medical Research and Materiel Command
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Bavari, Sina, Iversen, Patrick L., Stein, David A.
• Primary Examiner(s): VIVLEMORE, TRACY ANN
• Application Number:
  US11/264,444
• Publication Number:
  US 20060205693A1
• Time in Patent Office: 1,275 Days
• Field of Search: None
• US Class Current: 514/44.00R
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/31 of the backbone
• CPC Class Codes: C12N 2310/32 of the sugar
• CPC Class Codes: C12N 2310/3513 Protein; Peptide

Abstract

The invention provides antisense antiviral compounds and methods of their use in inhibiting of growth of and treating infection by viruses of the Filoviridae family.

Claims

1. An antiviral composition for treating an Ebola virus infection, comprising:

an antisense morpholino oligomer composed of morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5′

exocyclic carbon of an adjacent subunit, wherein the oligomer comprises a targeting sequence which forms a heteroduplex with a target sequence within the AUG start site region of Ebola VP35 mRNA, and wherein the antisense oligomer inhibits virus production, wherein the antisense oligomer has at least 12 contiguous bases from a targeting sequence selected from the group consisting of SEQ ID NOS;

21 -26.

2. The composition of claim 1, wherein the targeting sequence has the sequence of SEQ ID NO:

21.

3. The composition of claim 1, wherein the targeting sequence has the sequence of SEQ ID NO:

22.